Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian patients, explores the company’s expansion plans into China, Japan, and Southeast Asia, and the synergies in their partnerships with big pharma.
Finding the unique algorithm specifically engineered for pre-menopausal Asian [breast cancer] patients was an important step for us and was crucial in confirming the accuracy of our test
